Cancer-fighting antibodies with a one-two punch take aim at tumours
Bispecific antibodies, which target two proteins simultaneously, are seeing a surge in clinical adoption and commercial success. With over 20 approvals globally, these advanced cancer-fighting drugs generated $18 billion in sales in 2025.
Why it matters
This represents a significant shift in oncology treatment, offering more precise and effective therapeutic options for previously difficult-to-treat cancers.
Heidi Ledford reports for Nature from Seattle, Washington.
Search author on: PubMed Google Scholar
Bluesky Facebook LinkedIn Reddit Whatsapp X Bispecific antibodies (orange and yellow, artist’s illustration) grab onto two different proteins rather than the standard one. Credit: Thom Leach/Science Photo Library
Cancer-fighting drugs called bispecific antibodies are having a moment. A growing number are making their way into the clinic, and researchers are developing increasingly elaborate molecules with new capabilities.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in